Cytori Cell Therapy Receives Limited Approval in Japan
Cytori Therapeutics, Inc. announced that the Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine, enacted in November 2014.
Tokyo Osteoarthritis Clinic will begin to treat knee osteoarthritis patients with Cytori Cell Therapy immediately. The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated. The approval is not reimbursed by Japan's healthcare system and patients will be responsible for the costs.
Source: Cytori Therapeutics, Inc.
In the Japanese orthopaedic market, large joint reconstruction is the dominant segment. Learn more about the state of the market from ORTHOWORLD's intelligence report titled, The Japanese Orthopaedic Market.